AstraZenecas(LSE: AZN) (NYSE: AZN.US) promise to increase revenues to $45bn by 2023 has been met with plenty of scepticism. Its easy to see why, as this target will require the company to achieve a 75% increase on 2013sales within the next decade a tough target for a company thatis expecting sales to fall for the next two years.
This lofty target has sent Astrascrambling for growth. And over the past week or so, it seems as if Astras management has really ramped up the progress of their ambitious growth plan.
Multiple transactions
It has been a busy fortnight for Astra. On 24 October, the company reported that it had received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, or EMA regarding the marketing ofLynparza (olaparib), a new ovarian-cancer drug. While this approval and recommendation from the EMA does not constitute a full approval, its usually the case that recommendations put forward by the agency are followed across the continent. So, this development was great news for Astra.
A few days after theolaparib opinion, Astra received US Food and Drug Administration approval for the companysonce-daily XIGDUO XR drug, which has been designed to treat adults withtype 2 diabetes. Diabetes is one of the most prominent illnesses within the US, which means that the approval XIGDUO XR was a landmark victor for Astra.
Astras string of good news continued, with the announcement at the beginning of this month that the company had completed an asset swap with peerAlmirall.
The deal saw Astra pay Almirallapproximately $875m, with up to $1.2bn to be paid at a later date for the ownership of the rights for the development and commercialisation of Almiralls proprietary respiratory business portfolio. These rights includerevenues from Almiralls existing partnerships, as well as its pipeline of investigational novel therapies. This deal is likely to have a significant impact on Astras earnings.
And finally, it was announced today that Astrasglobal biologics research and development arm,MedImmune,has entered into an agreement to acquire Definiens. Definiens is aprivately held companythat has pioneered a world-leading data analysis technology, which dramatically improves the identification tumours in human tissue cells.
Readyfor growth
Theres no doubt that Astra has been busy recently and the companys acquisitions as well as drug approvals all add up. Indeed, it is now really starting to look as if Astra has the potential to hit its end-of-the-decade revenue targets as bolt-on acquisitions start to contribute to the bottom line.
Whats more, alongside the above acquisitions and approvals, Astra has more than tendrugs in late-stage trials or under regulatory review.Among the most significant are MEDI4736, which uses the bodys own immune system to fight tumours, and AZD9291, a lung cancer treatment.
All in all, it seems as if the company is really making progress in its quest for growth.
Defensive backbone
Every portfolio needs a selection of shares with defensive qualities like those of Astra. A selection of defensive shares with attractive dividend yields gives your portfolio a solid backbone, allowing you to sleep soundly at night.
With that in mind, I’m considering investing in several of the five FTSE shares highlighted withinthis exclusive wealth report.
All five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!
Justclick herefor the report — it’s free!
Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
